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Pemphigus and bullous pemphigoid are autoimmune 
bullous diseases of the skin. Pemphigus, an intraepider-
mal blistering disease, is characterized by autoantibod-
ies reactive with antigens located in the intercellular 
spaces or on the surfaces of epidermal cells. These anti-
bodies, which have recently been shown to activate com-
plement, appear to be the cause of the basic pathologic 
process of pemphigus, acantholysis. The complement 
system and the plasminogen-plasmin system may be im-
portant mediators in the detachment of epidermal cells. 
Bullous pemphigoid, a subepidermal blistering disease, 
is characterized by autoantibodies reactive with an an-
tigen located in the lamina Iucida region of the basement 
membrane zone. These autoantibodies, which will avidly 
fix complement, appear to mediate subepidermal sepa-
ration by attraction of a variety of inflammatory cells. 
Anaphylatoxins, released by activation of C4 and C3, or 
specific lgE antibodies, may activate mast cells with 
release of ECF- A attracting eosinophils. With activation 
of C5, C5a is released which could attract polymorpho-
nuclear leukocytes. Antigen-specific lymphocytes, 
which can also contribute histamine releasing sub-
stances, may also be involved. The exact mechanism by 
which the epidermis separates from the dermis in bul-
lous pemphigoid, however, remains unresolved. 
Pemphigus and bullous pemphigo id are members of the 
chronic nonhereditary blistering skin diseases of man. Based 
upon simi lar histopathologic and immunopathologic findings, 
pemphigus may be considered a disease group which includes 
pemphigus vu lgari s, pemphigus vegetans, pemphigus foliaceus, 
pemphigus erythematosus, B razilian pemphigus foliaceus or 
" fo go selvagem" and drug-induced pemphigus usually assoc i-
ated with d-pen icillamine administration. By histopathology, 
t he pemphigus group of di seases may be separated into deep 
and superficial forms. Pemphigus vulgaris, and the rare variant 
pemphigus vegetans exh ibit suprabasilar intraepidermal bulla 
formation, while pemphigus foliaceus and its variants exhibit 
superficial in traepidermal bulla formation. All forms of pem-
phigus share t he histologic feature of acantholysis or loss of 
cohes ion of epidermal cell s [1,2]. This acantholytic mechanism 
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Abbreviations: 
ADCC: antibody dependent cellular cytotoxicity 
BMZ: basement membrane zone 
C: complement 
ECF-A: eosinophilic chemotactic factor of anaphylaxis 
ESM: eosinophil colony stimulating material 
HMW -NCF: high molecular weight neutrophil chemotactic factor 
JCS: intercellular substance 
IEM: immunoelectron microscopy 
IF: immunofluorescence 
PA: plasminogen activator 
PMNL: polymorphonuclear leukocyte(s) 
SRS-A: slow reacting substance of anaphylaxis 
in pemphigus has received considerable investigative attention 
in recent years. 
Bullous pemphigoid, on the other hand, is a bullous disorder 
which affects mainly middle-aged and older persons [2]. Like 
pemphigus , bullous pemphigoid is a member of a group of 
diseases which share similar histopathologic and immunopath-
ologic findings. Other members of this disease group include 
cicatricial pemphigoid, localized scarring pemphigoid (Brunst-
ing-Perry type), and herpes gestationis. Lesions of bullous 
pemphigoid may appear as grouped bullae of vesicles arising in 
greatest numbers in flexural areas (groin, axillae, anticubetal 
fossae, etc.) usually healing without scarring. Remissions and 
exacerbations usually occur during a 6- 10 year course of the 
disease, and spontaneous complete resolution is customary. 
Histopathologically, bullous pemphigoid is a subepidermal blis-
tering skin disease. 
\ PEMPHIGUS 
Pemphigus is an autoimmune disease of the skin . By direct 
immunofluorescence (IF) staining, numerous studies have con-
firmed the presence of serum autoantibodies with reactivity for 
antigens localized to t he intercellular substance (ICS) of epi-
dermis or the surfaces of individual epidermal cells [1 - 4] . These 
autoantibodies are of the IgG type, reside in all subclasses of 
lgG [5], and are present in all types of pemphigus, an additional 
feature which unifies members of this disease group. Levels of 
pemphigus ant ibodies often fluctuate with activity of disease, 
being high during periods of disease activity and low or entirely 
absent during periods of remission [6,7] . 
In recent years, considerable investigative effort has been 
focused upon the antigens reactive with pemphigus antibodies. 
To review a ll such attempts published thus far would be beyond 
the scope of this review. Suffice it to say, some controversy still 
exists concerning the size of the antigen or antigens. Diaz and 
co-workers [8] isolated a glycoprotein from human saliva (pre-
sumably produced by oral mucosa cells) with a molecular weight 
of approximately 50,000 daltons, while Stanley et al [9] have 
identified a 210,000 dalton protein which when reduced has 
130,000 and 80,000 molecular weight chains. Stanley and co-
workers [10] have also recently shown some but not alf pem-
phigus foliaceus sera are reactive with ant igens which differ 
from those associated with pemphigus vulgaris . Whatever their 
composition, t hese antigens are clearly produced by and ex-
pressed on the surfaces of epidermal cells [ 4,11] and appear to 
be important in cell -cell adhesion [12]. 
Several lines of evidence suggest that antibodies found in the 
sera of patients with pemphigus are the cause of the disease 
process. By direct IF methods, early acantholytic areas of 
pemphigus skin and oral lesions have heavy ICS deposits of 
lgG [13,14]. Thus, pemphigus antibodies, in addition to their 
presence in serum, are capable of leaving the circulation and 
reacting with epidermal cell surface antigens in vivo. In addi-
t ion to finding IgG deposits in these skin lesions, a variety of 
complement components, including C1q, C4, C3 (Fig lA), B 
and properdin have also been identified in these ICS deposits 
[15-17]. 
The first convincing evidence that the antibodies found in 
sera of pemphigus patients are responsible for acantholysis was 
presented several years ago by Michel, Schiltz, and co-workers 
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[18,19]. Wi th explants of normal hu_man s ~in i!1 t he pr~sence 
of pemphigus lgG in organ cul ture, htstologtc evtdence of acan-
tholysis occurred wi thin 48- 72 h. Late r, Fa rb , Singer, and co-
workers (20,21] demonstrated t hat epidermal cell detachment 
occurs when pemphigus lgG was added to monolayers of epi -
dermal cells in cul ture. They fur ther showed that pemphigus 
IgG would stimulate the release of proteinases in th~ ir cul ture 
systems, studies confirmed by Woo eta! [22]. Hashtmoto and 
co-workers [23) recent ly ident ified the proteinase released by 
cul tured epidermal cells when t reated wit h pemphigus lgG as 
plasminogen activato r (PA) . They have proposed that activa -
tion of plas minogen to plasmin by P A may be responsible for 
acantholysis. T o substan t iate thi s hypothes is fur ther, Morioka, 
J ensen, and Lazarus [24] have recent ly shown that t he addi t ion 
of plasmin to the epidermal cul ture systems will resul t in 
epidermal ce ll detachment . 
As the above investigat ions were a ll performed in t he absence 
of complement [18- 21,23], the involvement of the complement 
system in t he process of aca nt holys is has remained cont rover-
sial. Despite the fact t hat complement deposits a re present in 
pemphigus lesions by direct IF [15- 17], ea rly attempts to dem-
onstrate that pemphigus antibodies would fix complement 
fa iled [25]. Later, Nishikawa et a! [26) and Hashimoto et a! 
[27) we re ab le to demonstrate by in vit ro complement IF 
staining t hat some pemphigus antibodies would fi x complement 
to normal human skin. We have recently confirmed their 
studies and extended t hem by showing that pemphigus ant i-
bodies will fi x complement to orga n cul ture skin explants and 
to epidermal monolaye rs (Fig 1B) in t issue cul ture [11] . As 
t hese antibodies would fix the early co mponents Clq and C4, 
and in addi t ion C3 (Table I) , pemphigus ant ibodies appear to 
fix complement via t he classical pathway. 
The next question we wished to address was whether com-
plement might enhance pemphigus IgG induced detachment of 
epidermal ce ll s in cul ture. Thus, we chose to ut ilize a system 
as desc ri bed by Woo and co-workers [22], but choosing a 
pemphigus IgG concent ration (1 mg/ ml ) reported by them to 
be insufficient to cause detachment of monolaye rs of cul tured 
epidermal cells. T hus, in our system, minimal cell detachment 
occurred when 1 mg/ml pemphigus was added to the 48- h 
cul tures a lone. When complement was added lo such cultures 
FIG 1. Immun oflu o resce nce (IF) 
studies in pemphigus. (a) Direct IF 
staining of a n early acant holytic pem -
phigus skin les ion using labeled a nti hu-
man C3 a nt iserum . Intercellula r sub-
stance sta ining is evident. x 400 (origi-
na l magnification). (b) Mouse epide rma l 
monolaye r incubated with 3 mg/ ml pem-
phigus lgG. Following incubation with 
complement, t he cells were t reated with 
labeled a nt ihuma n C3 . Positive speck led 
staining on t he ce ll sur faces is evident . 
x 625 (o rigina l magnification). 
TABLE I. In vitro complement staining reactions with mouse 
epidermal monola.yers and organ cultured normal human skin" 
Pemphigus IgG 
(3 mg/.nl) 
Norma l human lgG 
(3 mg/ ml ) 
Complement 
treatment• 
Staining reaction ' 
Clq C4 C3 
c ++ +++ +++ 
NoC 
Purified Cl q ++ 
C 56· c , 30 min 
C2 deficient serum ++ ++ 
c 
NoC 
• Modified from [11] . 
• C: 10% ABnormal huma n serum was used as t he source of comple-
ment. 
·· - to +++: In tensity of sta ining. Speckled patte rn in epidermal 
monolayers or ICS staining in organ cul tured skin. Resul ts obta ined 
using epidermal monolayers or organ cul ture skm were tdent tcal. 
(T able II) , s ignificant detachment of cultured epidermal cells 
became apparent [28]. By using C1q depleted serum of _heat 
inactivated serum as the complement source (T able II), eptder-
mal cell detachment was completely inh ibited. Depletion of 
plasminogen from both the pemphigus lgG fractions and the 
complement source on the other hand failed to inhibi t cell 
detachment*. Thus, complement activation by pemphigus an -
t ibodies prov ides an addi t ional mechanism for loss of epidermal 
cell cohesion in addi t ion to the plasminogen-plasmin system. 
Passive transfer studies also suggest t hat pemphigus antibod-
ies a re pathogenetic. Buschard et a! [29] developed a model in 
athymic mice using explanted oral mucosa. One week fo llowing 
explantation, res ant ibodies were injected int raperi toneally. 
Binding of ICS ant ibodjes could be detected and histologic 
evidence of aca ntholysis could be seen in the sites of the oral 
mucosa l explants. More recently, da ily i.p. injections of pem-
phigus se rum into 24 h old mice by Anhalt et al [30) resul ted 
• Kawana S, Geoghegan WD , J ordon RE: Complement fix ation by 
pemphigus a nt ibody. II. Complement enhanced detachment of epider-
mal cells. Submi tted for publication. 
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in bliste ring sk in lesions at about 1 week. These , · in lesions 
were hi stologica lly identi cal to true pemphigus lesions a nd with 
binding of ICS antibodies to t he mouse skin. These studies 
have recently been confirmed and extended by Peterson and 
Wuepper [31] who, in addition to passively transferring t he 
disease in neonatal mice, used a rabbit antiserum to purified 
pemphigus antigen to induce the experimental lesions. Thus, 
the disease pemphigus has been successfully passively trans-
ferred to experimental animals. 
Mechanistically, then acantholysis in pemphigus appears to 
result from the interaction of pemphigus antibodies with epi-
dermal cell surface antigens t hought to be important in cell-
cell adhes ion. Both activated complement and plasmin appear 
to mediate the ce ll detachment associated with th is disease 
process (Fig 2). The role ce ll s play, such as eosinophils, which 
are commonly found in early infiltrates, remains to be deter-
mined. 
BULLOUS PEMPHIGOID 
Like pemphigus, bullous pemphigo id is also an autoimmune 
bullous skin disease. This subepidermal blistering disease, how-
ever, is characteri zed by circulating lgG autoantibodies which 
react wi th ant igens located in the lamina Iucida region of the 
basement membrane zone (BMZ) [1,32,33]. The antigen(s) 
reactive with t hese ant ibodies, which have been part ially char-
acteri zed [34,35], appear to be produced by basal keratinocytes 
[4] and deposited along the BMZ [36]. 
By histopathology, a va riety of inflammato ry ce lls have been 
identified in bullous pemphigoid infiltrates. Non inf1ammatory 
appearing lesions show a sparse perivascula r infiltrate of eosin-
ophils and mononuclear cells. By contrast, inflammatory le-
sions show a dense perivascular and subepidermal infiltrate 
consisting predominantly of eosinophils with mononuclear cells 
and polymorphonuclea r leukocytes (PMNL) present in smaller 
numbers. Low eosinophil and high eosinophil lesions [37,38] 
TABLE II. Epidermal cell deiachm.eni by phase microscopy 
Pemphigus IgG 
(1 mg/ml) 
NormallgG 
(1 mg/ml) 
c 
Complement 
t reatme nt" 
No C 
C 56"C, 30 min 
Clq depleted C 
c 
No C 
72 Hours 
detac hment• 
+++ 
"C: 10% ABno rmal human serum absorbed with murine epidermal 
cells (complement source). 
1
'- to +++: The extent of cell detachment visualized by phase 
microscopy. 
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have been noted by several investigators; close light microscopic 
and electron microscopic studies of very early lesions reveal 
prominent mast cells in the reticular and papillary dermis 
showing focal irregular loss of granules as well as degranulation, 
karyorhexis, and karyolysis of eosinophils [39,40]. Tissue injury 
which precedes frank dermal-epidermal separation is also 
present in early lesions [41]. Basal keratinocytes show loss of 
hemidesmosomes, and widening of intercellular spaces. Vascu-
lar injury is apparent with endothelial hypertrophy, focal lu-
minal obliteration, and focal endothelial cell death [39]. 
The earliest clues to the pathogenic mechanisms which might 
be responsible for the t issue injury outlined above came from 
IF and immunoelectron microscopic (IEM) studies. In vivo 
bound gamma globu lin was noted at the BMZ in lesions of 
bullous pemphigoid [32]. Later, classes of immunoglobulins 
were defined and evidence of complement activation [ 42] was 
noted. Most commonly, IgG and/or C3 are found at the BMZ 
(Fig 3). IgA and lgM are found in about 25 % of the cases 
[38,43]. In addition, IgE has been noted at the BMZ (44] and 
on mast cell surfaces in involved skin of bullous pemphigoid 
patients [45]. Evidence for classical complement pathway ac-
t ivation [ 46,4 7] as well as a lternate pathway activation has 
been established (48-50]. {3 1H globulin , a cofactor for C3biNA, 
has also been detected using IF studies in involved skin [51-
53]. More recently, Dahl and associates [54] have demonstrated 
deposition of t he membrane attack complex (C5- 9) in bullous 
pemphigoid lesions (Table III). 
IEM of lesional sk in has localized the immunoglobulin dep-
osition to the sub-basalar lamina Iucida area [33]. Others have 
furt her noted C3 in this location [55], as well as "lumpy-bumpy" 
immunoglobulin deposition sub-basally and intercellularly sug-
gesting immune complex deposition [56]. Immune complexes 
have a lso been noted in some BP patients with active disease, 
but negative indirect IF [57]. This suggests that bullous pem-
phigoid antigen may be produced in excess and may even 
circulate, thus providing a nidus for immune complex forma-
tion. Immune complexes have also been detected in bullous 
pemphigoid blister f1uids [58]. 
The IF studies of lesional tissue provide evidence that the 
humoral aspect of the immune system plays a role in lesion 
formation , with a cellular component as well. This latter evi-
dence, however, is more difficult to interpret. 
The mast cell cou ld be viewed as a bridge linking t he cellular 
and humoral components in lesion development. It is observed 
to be present and to have a degranulated appearance in early 
lesional tissue [59] . Under the influence of an appropriate 
stimulus such as IgE, C3a or C4a [60], the mast cell will release 
histamine, slow reacting substance of anaphylaxis (SRS-A), 
eosinophilic chemotactic factor of anaphylaxis (ECF-A), high 
molecular weight neutrophil chemotactic factor (HMW-NCF) 
platelet-activating factors, and enzymes. C4a and C3a are de-
rived following the activation of C4 and C3 [61] . As many 
FIG 2. Proposed mechanism for pem-
phigus acantholysis. 
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TABLE III. Summary of compLement immunofLuorescent studies in 
buLLous pemphigoid f 44,46,48- 54] 
Components identified 
in skin lesions 
Clq 
C4 
C3 
C5 
C5-9 (MAC)" 
Factor B 
/31H globulin 
Properdin 
a MAC = membrane attack complex. 
Components fixed by 
BMZ-ant ibody 
in vitro 
Cl q 
C4 
C3 
C5 
C5-9 (MAC)" 
Factor B 
/31H globulin 
Properdin 
bullous pemphigoid antibodies have been shown to activate 
complement in vivo and in vi tro, one could postulate that 
complement activation, rather t han causing direct t issue injury, 
triggers mast cell degranulation with histamine release result-
ing in "leakiness" of blood vessels and chemoattraction of 
eosinophils, (ECF-A) and PMNL (HMW-NCF). C4a, C3a and 
C5a produced by complement activat ion could further amplify 
the chemoattractive effect [62,63]. 
Examination of blister fluid helps to substantiate t his theory 
of pathogenesis. Complement activation leading to a decreased 
CH50 of blister fluid as compared to serum CH50 in the same 
patient has been observed [64]. Immune complexes which form 
and have been detected in these blister fluids [58] might con-
tribute to these depressed blister fluid CH50 levels. This reduced 
CH50 is associated with increased chemotactic activi ty of blister 
fluid [65 ]. A number of immune modulating factors have also 
been observed in bullous pemphigoid blister f1uid, including 
ECF-A [66,67], eosinophil co lony stimulati ng material or ESM 
[68], lymphocyte chemotactic material [69], and prostaglandin 
E 2 [70) . Enzymatic activity in blister fluid has also been noted 
[71] . These findings can be in terp reted as evidence for humora l 
and cellular activity in the bullous pemphigoid les ion. 
The difficulty lies in determining a causa l relationship be-
tween cellular and humora l aspects and in proving which if any 
actually produces the histologic change of dermal epidermal 
separation. Dubertret et a! [72) using histologic studies propose 
F IG 3. IF studies in bullous pemphi -
goid. (a) Direct IF stain ing of ski n adja-
cent to a lesion of bullous pemphigoid 
using labeled a nti human C3. Staini ng of 
t he basement membrane zone is evident. 
x 250 (original magn ification) . (b) In 
vitro complement IF sta ining of normal 
human skin using serum from a patient 
with bullous pemphigoid and labeled a n-
t ihuma n C4. Staining of the basement 
membrane zone is evident. x 250 (origi-
nal magnification). 
that direct keratinocytic killing and enzyme release by eosino-
phils leads to blister formation. T he eosinophil , abundant in 
most inf1ammatory lesions of bullous pemphigoid is capable of 
antibody dependent cellular cytotoxicity (ADCC) killing of a 
variety of cell types in culture [73]. An associated eosinophilia 
is often noted in cases of bullous pemphigoid [74]. 
Attempts to develop an in vitro model have foc used on the 
role of complement and PMNL in lesion formation. Anhalt et 
a! have produced microblebbing and a PMNL rich inflamma-
tory infil t rate by injecting bullous pemphigoid antibody into 
rabbit cornea [75]. Gammon et a!, using an in vitro model of 
t he dermal-epidermal junction, have demonstrated directed 
migration of PMNL to the BMZ in the presence of bullous 
pemphigoid antibody and complement [76]. Although activa-
tion of PMNL has been demonstrated [77], no true separation 
of epidermis from dermis has been demonstrated in vitro using 
bullous pemphigoid ant ibody and complement [78] or PMNL 
[76,79,80]. It appears then t hat some other cell(s) or factor(s) 
may be necessary for fulllesional development. Indeed, t he role 
of the PMNL may be to elaborate ECF-A after ingestion of 
immune complexes [58,67]. However, other possible roles for 
the PMNL could be elaboration of lytic enzymes or direct 
keratinocyte killing or injury via ADCC. 
The mononuclear cell is also present in inflammatory infil-
trates of bullous pemphigoid. The role of t he lymphocyte and/ 
or monocyte macrophage in bullous pemphigoid is poorly 
understood. As noted above, a lymphocyte chemotactic factor 
has been isolated from blister bluid [69]. The source of t his 
factor is unknown, alt hough peripheral blood mononuclear 
(Ficoll Hypaque separated cells) will elaborate a factor chem-
otactic for lymphocytes when stimulated with mitogen in vitro 
[81). 
It has also been noted that PPD-specific lymphocytes will 
accumulate within and beneath artificial blisters overlying der-
mal injections of PPD in vivo [82]. Thus, lymphocytes may 
accumulate in response to specific ant igen and/or chemoattrac-
tants elaborated by stimulated monocytes or other mononuclear 
cells. The role of t he lymphocyte is also unclear since these 
cells are capable of a number of varied activities . One possible 
role for the lymphocyte is as a source of histam ine releasing 
facto rs [83). This would permit long-term stimulation of mast 
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cells to e labo rate chemoattractants a nd histamine thus pe rpet-
uating t he immune respo nse locally. Another possible role 
would be direct cytotox ic e ffect on basal kerati nocytes. These 
functions rem a in to be experime n ta lly tested in vit ro using a 
model that is capable of fulllesional expression, t hat is, dermal-
epidermal separatio n , s uch as orga n cu lt ure or ep iderma l mon-
olayers on dermal-epidermal junctio n -like glycoprote in matrix. 
Based on t he ev ide nce presen ted, we propose t he following 
mechanism of tissue injury in bullous pemphigoid: Bullous 
pemphigoid antigen in some way rendered immunoge nic to 
stimulate an a n t iself clone of B cell /plasma cell s. Va rious 
classes of a n tibu llous pemphigoid antigen antibodies are elab-
orated w ith l gG predominatin g. The specific l gG binds bullous 
pemphigoid a n t igen in its normal lami na Iucida location a nd 
begins fixing a nd activating complemen t (Fig 4). Among other 
thi ngs, C3a a nd C4a are elaborated. Mast cells degranulate 
elaborati ng ECF -A, HMW -NCF, perhaps ESM, histamine, and 
e nzymes. Eosinoph il s a nd PMNLs a re recruited and possibly 
bind via C3b receptors to t he dermal-epide rm a l junction. By 
direct cytotox ic actio n o r because of enzymes elaborated, a 
rupture of t he dermal-epidermal attachment is produced a nd a 
bliste r formed . Lymphocytes in t he a rea elaborate HRF (his-
tam ine re leasing fa cto r) to up regulate mast cell degranu lation 
a nd t he lesions progressed to s how bullae, o fte n in groups 
extending over weeks a nd mont hs. This proposed model would 
account for most of the findin gs to date in bullous pe mphigoid 
a nd the tas k now is to iso late a nd sequence t he discrete events 
leadin g to clinical expressio n of t he di sease. 
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